Best Practices in Evaluating Novel Biomarker Fit for Purpose and Translatability

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

This chapter discusses various tactical aspects to consider when evaluating novel biomarker translatability. The evaluation procedures warrant careful attention in order to leverage the most appropriate traditional and novel biomarkers in the relevant biological matrices. Integration of biomarkers into clinical protocols requires incorporation of biomarker analysis into one of the study objectives. The chapter also describes the use of fit-for-purpose biomarkers in different phases of drug development. When translating a biomarker from preclinical to clinical studies, the species specificity of the assay should be evaluated. Evidence-based protocols for sample collection should be developed and implemented for each biomarker analyzed. When multiple biomarkers are to be analyzed, multiple types of collection containers/tubes may be necessary. The frequency of sample shipments should be determined based on storage space available at the site, stability of samples, and practical factors including personnel time required and cost.

Original languageEnglish (US)
Title of host publicationDrug Discovery Toxicology
Subtitle of host publicationFrom Target Assessment to Translational Biomarkers
Publisherwiley
Pages489-494
Number of pages6
ISBN (Electronic)9781119053248
ISBN (Print)9781119053330
DOIs
StatePublished - Jan 1 2016

Fingerprint

Biomarkers
Practice Guidelines
Species Specificity
Clinical Protocols
Containers
Assays
Personnel
Costs and Cost Analysis
Pharmaceutical Preparations
Costs

Keywords

  • Biological matrix selection
  • Biomarkers
  • Drug development
  • Fit-for-purpose testing
  • Human sample collection
  • Sample collection device

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Baker, A. F. (2016). Best Practices in Evaluating Novel Biomarker Fit for Purpose and Translatability. In Drug Discovery Toxicology: From Target Assessment to Translational Biomarkers (pp. 489-494). wiley. https://doi.org/10.1002/9781119053248.ch42

Best Practices in Evaluating Novel Biomarker Fit for Purpose and Translatability. / Baker, Amanda F.

Drug Discovery Toxicology: From Target Assessment to Translational Biomarkers. wiley, 2016. p. 489-494.

Research output: Chapter in Book/Report/Conference proceedingChapter

Baker, AF 2016, Best Practices in Evaluating Novel Biomarker Fit for Purpose and Translatability. in Drug Discovery Toxicology: From Target Assessment to Translational Biomarkers. wiley, pp. 489-494. https://doi.org/10.1002/9781119053248.ch42
Baker AF. Best Practices in Evaluating Novel Biomarker Fit for Purpose and Translatability. In Drug Discovery Toxicology: From Target Assessment to Translational Biomarkers. wiley. 2016. p. 489-494 https://doi.org/10.1002/9781119053248.ch42
Baker, Amanda F. / Best Practices in Evaluating Novel Biomarker Fit for Purpose and Translatability. Drug Discovery Toxicology: From Target Assessment to Translational Biomarkers. wiley, 2016. pp. 489-494
@inbook{02851cd722cc43a3ae1092a758fcbcbd,
title = "Best Practices in Evaluating Novel Biomarker Fit for Purpose and Translatability",
abstract = "This chapter discusses various tactical aspects to consider when evaluating novel biomarker translatability. The evaluation procedures warrant careful attention in order to leverage the most appropriate traditional and novel biomarkers in the relevant biological matrices. Integration of biomarkers into clinical protocols requires incorporation of biomarker analysis into one of the study objectives. The chapter also describes the use of fit-for-purpose biomarkers in different phases of drug development. When translating a biomarker from preclinical to clinical studies, the species specificity of the assay should be evaluated. Evidence-based protocols for sample collection should be developed and implemented for each biomarker analyzed. When multiple biomarkers are to be analyzed, multiple types of collection containers/tubes may be necessary. The frequency of sample shipments should be determined based on storage space available at the site, stability of samples, and practical factors including personnel time required and cost.",
keywords = "Biological matrix selection, Biomarkers, Drug development, Fit-for-purpose testing, Human sample collection, Sample collection device",
author = "Baker, {Amanda F}",
year = "2016",
month = "1",
day = "1",
doi = "10.1002/9781119053248.ch42",
language = "English (US)",
isbn = "9781119053330",
pages = "489--494",
booktitle = "Drug Discovery Toxicology",
publisher = "wiley",

}

TY - CHAP

T1 - Best Practices in Evaluating Novel Biomarker Fit for Purpose and Translatability

AU - Baker, Amanda F

PY - 2016/1/1

Y1 - 2016/1/1

N2 - This chapter discusses various tactical aspects to consider when evaluating novel biomarker translatability. The evaluation procedures warrant careful attention in order to leverage the most appropriate traditional and novel biomarkers in the relevant biological matrices. Integration of biomarkers into clinical protocols requires incorporation of biomarker analysis into one of the study objectives. The chapter also describes the use of fit-for-purpose biomarkers in different phases of drug development. When translating a biomarker from preclinical to clinical studies, the species specificity of the assay should be evaluated. Evidence-based protocols for sample collection should be developed and implemented for each biomarker analyzed. When multiple biomarkers are to be analyzed, multiple types of collection containers/tubes may be necessary. The frequency of sample shipments should be determined based on storage space available at the site, stability of samples, and practical factors including personnel time required and cost.

AB - This chapter discusses various tactical aspects to consider when evaluating novel biomarker translatability. The evaluation procedures warrant careful attention in order to leverage the most appropriate traditional and novel biomarkers in the relevant biological matrices. Integration of biomarkers into clinical protocols requires incorporation of biomarker analysis into one of the study objectives. The chapter also describes the use of fit-for-purpose biomarkers in different phases of drug development. When translating a biomarker from preclinical to clinical studies, the species specificity of the assay should be evaluated. Evidence-based protocols for sample collection should be developed and implemented for each biomarker analyzed. When multiple biomarkers are to be analyzed, multiple types of collection containers/tubes may be necessary. The frequency of sample shipments should be determined based on storage space available at the site, stability of samples, and practical factors including personnel time required and cost.

KW - Biological matrix selection

KW - Biomarkers

KW - Drug development

KW - Fit-for-purpose testing

KW - Human sample collection

KW - Sample collection device

UR - http://www.scopus.com/inward/record.url?scp=85019967208&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019967208&partnerID=8YFLogxK

U2 - 10.1002/9781119053248.ch42

DO - 10.1002/9781119053248.ch42

M3 - Chapter

AN - SCOPUS:85019967208

SN - 9781119053330

SP - 489

EP - 494

BT - Drug Discovery Toxicology

PB - wiley

ER -